Amgen Raises Q3 2025 Dividend 6% to $2.38

Amgen's declaration of a $2.38 quarterly dividend for Q3 2025 — a 6% year-over-year increase — reinforces the company's emphasis on returning capital to shareholders alongside share repurchases. The move is consistent with Amgen's stated capital-allocation priorities, which include sustained dividend growth and ongoing buybacks. Fundamentals: Amgen reported total product sales of $35,148 million in FY 2025, up roughly 10% year-over-year, with the U.S. accounting for approximately 73% of product sales and the rest of world about 27%. That revenue growth has been driven by several established products and recent label expansions, even as net product pricing faced headwinds (reported net price decline of about 3%) related to biosimilar and competitive pressure. Moat and risks: Amgen's structural advantages remain patent protection on high-value biologics, manufacturing scale across owned and contract facilities, and physician/patient switching dynamics for biologic therapies. These factors support a narrow economic moat, but the company faces clear erosion risks where patents have recently expired in the U.S. and are slated to lapse in select international markets later this year — increasing susceptibility to biosimilar competition for products such as denosumab (Prolia/XGEVA) and other biologics. Ongoing legal and regulatory matters (including patent disputes and litigation involving competitors and payers) and macro pressures from biosimilars and pricing reforms are material considerations for dividend sustainability.

The Q3 2025 dividend increase complements Amgen's broader capital-return program, which combines dividend growth with sizable share-repurchase authorization. Reported capital-allocation priorities emphasize supporting a rising dividend while using buybacks to manage capital structure. For income-focused investors, the increase signals management's intent to prioritize predictable cash returns even as the company navigates pipeline investments and patent transitions. Near-term considerations include free-cash-generation trends, the pace and impact of biosimilar entries on legacy product sales, and legal outcomes that could affect cash flows. Investors should monitor quarterly cash-flow disclosures and any updates to repurchase authorizations or dividend policy in upcoming reports.

Pipeline momentum remains central to offsetting patent-related erosion. Key development-stage assets and recent program activity include MariTide (maridebart cafraglutide), for which multiple Phase 3 studies were initiated in 2025 following positive Phase 2b 52-week data reported in late 2024. Additional focus areas include label expansions and late-stage work for TEZSPIRE, EVENITY, BLINCYTO and Repatha, as well as collaborations in oncology and immunology. Manufacturing capacity expansions (Ohio, North Carolina, Puerto Rico and other sites) and recent facility licensure support scale advantages but require continued execution. Near-term catalysts that could materially affect the dividend outlook or stock sentiment include Phase 3 readouts for MariTide and other late-stage programs, commercialization performance for recently acquired or expanded products, and outcomes in ongoing patent and payer litigation.